Which activity best describes pharmacovigilance after a drug is marketed?

• A. Reassessing drug risks based on new data learned after the drug is marketed, and recommending ways of managing that risk
• B. Conducting preclinical animal testing
• C. Marketing the drug without post-marketing surveillance
• D. Limiting to the initial clinical trials

Answer: (A)

After a drug is approved and on the market, pharmacovigilance means continually monitoring its safety as real-world use reveals new information. The key idea is to detect new adverse effects, reassess the overall benefit–risk balance with fresh data, and recommend concrete risk-management actions. This can include updating labeling, adding warnings, changing dosing guidance, or restricting who can use the drug, all aimed at keeping patients safe as more experiences with the drug accumulate.

Preclinical animal testing happens before humans are exposed to the drug, so it isn’t what pharmacovigilance after marketing refers to. Marketing a drug without post-marketing surveillance would ignore real-world safety signals. Limiting activities to initial clinical trials would end the ongoing assessment of safety once the drug is on the market.